NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.05
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | 89.0K |
| Gross Profit | — | — | — | — | (89.0K) |
| Operating Expenses | |||||
| R&D Expense | 6.2M | 6.2M | 5.7M | 7.3M | 6.4M |
| SG&A Expense | 4.9M | 4.9M | 4.2M | 4.8M | 7.0M |
| General & Admin Expense | 4.9M | 4.9M | 4.2M | 4.8M | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.1M | 11.1M | 9.9M | 12.0M | 13.5M |
| Cost and Expenses | 11.1M | 11.1M | 9.9M | 12.0M | 13.6M |
| Operating Income (EBIT) | (11.1M) | (11.1M) | (9.9M) | (12.0M) | (13.6M) |
| Non-Operating | |||||
| Interest Income | — | 13.0K | 2.0K | 178.0K | 91.0K |
| Interest Expense | 17.0K | — | 311.0K | 550.0K | 15.0K |
| Net Interest Income | (17.0K) | 13.0K | (309.0K) | (372.0K) | 76.0K |
| Other Non-Op Income/Expense | (40.0K) | (40.0K) | (308.0K) | 1.9M | 1.2M |
| Non-Operating Income (excl Interest) | — | 40.0K | (3.0K) | (2.4M) | (1.2M) |
| EBT (Pre-Tax Income) | (11.1M) | (11.1M) | (10.2M) | (10.1M) | (12.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.1M) | (11.1M) | (10.2M) | (10.1M) | (12.3M) |
| Earnings from Cont. Ops | (11.1M) | (11.1M) | (10.2M) | (10.1M) | (12.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.1M) | (11.1M) | (10.2M) | (11.3M) | (12.3M) |
| Per Share | |||||
| Basic EPS | ($0.45) | ($0.44) | ($0.55) | ($0.83) | ($1.07) |
| Diluted EPS | ($0.45) | ($0.44) | ($0.55) | ($0.83) | ($1.07) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 25.6M | 25.5M | 18.6M | 13.6M | 11.5M |
| Diluted Shares Outstanding | 25.6M | 25.5M | 18.6M | 13.6M | 11.5M |
| Profitability Metrics | |||||
| EBITDA | (11.1M) | (11.1M) | (9.9M) | (9.6M) | (12.2M) |
| D&A | 16.0K | 16.0K | 22.0K | 21.0K | 89.0K |
| EBIT | (11.1M) | (11.1M) | (9.9M) | (9.7M) | (12.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025